Computational modeling of intraocular drug delivery supplied by porous implants

Abootorabi, Seyedalireza; Tripathi, Abhimanyu; Yu, Huidan; Dávila, Lílian P.

doi:10.1007/s13346-020-00878-2

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same equations can be used to describe the transport of molecules from the sclera to the vitreous, a scenario corresponding to implants inserted on the outer surface of the sclera. The case of a drug diffusing through such an implant to enter the sclera, later reaching the choroid and retina, was recently modelled in silico [1]. The model revealed the influence of implant porosity on the controlled release of drugs and suggested parameters that could be tailored to individual needs [1].…”

Section: Implants/port-deliverymentioning

confidence: 99%

“…The case of a drug diffusing through such an implant to enter the sclera, later reaching the choroid and retina, was recently modelled in silico [1]. The model revealed the influence of implant porosity on the controlled release of drugs and suggested parameters that could be tailored to individual needs [1]. Kotha and Murtomäki also modelled drug release from a scleral implant, with the difference that choroidal blood flow was modelled explicitly [160].…”

Section: Implants/port-deliverymentioning

confidence: 99%

See 1 more Smart Citation

Advancing treatment of retinal disease through in silico trials

2023

View full text Add to dashboard Cite

Treating retinal diseases to prevent sight loss is an increasingly important challenge. Thanks to the configuration of the eye, the retina can be examined relatively easily in situ. Owing to recent technological development in scanning devices, much progress has been made in understanding the structure of the retina and characterising retinal biomarkers. However, treatment options remain limited and are often of low efficiency and efficacy.In recent years, the concept of in silico clinical trials has been adopted by many pharmaceutical companies to optimise and accelerate the development of therapeutics. In silico clinical trials rely on the use of mathematical models based on the physical and biochemical mechanisms underpinning a biological system. With appropriate simplifications and assumptions, one can generate computer simulations of various treatment regimens, new therapeutic molecules, delivery strategies and so forth, rapidly and at a fraction of the cost required for the equivalent experiments. Such simulations have the potential not only to hasten the development of therapies and strategies but also tooptimise the use of existing therapeutics.In this paper, we review the state-of-the-art in in silico models of the retina for mathematicians, biomedical scientists and clinicians, highlighting the challenges to developing in silico clinical trials. Throughout this paper, we highlight key findings from in silico models about the physiology of the retina in health and disease. We describe the main building blocks of in silico clinical trials and identify challenges to developing in silico clinical trials of retinal diseases.

show abstract

Section: Implants/port-deliverymentioning

confidence: 99%

Section: Implants/port-deliverymentioning

confidence: 99%

Advancing treatment of retinal disease through in silico trials

2023

View full text Add to dashboard Cite

show abstract

“…Several papers have studied the PK modeling of drugs after being injected directly into the vitreous [ 152 - 162 ]. Other studies have addressed the PK modeling of drugs after being delivered directly or within a DDS through the periocular [ 163 - 169 ] or topical routes [ 170 - 175 ]. Here, this section covers papers that studied PK modeling of drugs released from DDSs after intravitreal injection.…”

Section: Ocular Pharmacokinetic Modeling Of Drugs Released From Intra...mentioning

confidence: 99%